The handheld system supports point-of-care fractional exhaled nitric oxide testing in adults and pediatric patients.

MGC Diagnostics has introduced Fenom Flo, a portable fractional exhaled nitric oxide (FeNO) monitoring system that uses a six-second breath test for respiratory assessment in adults and pediatric patients ages 7 years and older.

The handheld, point-of-care device is the only portable FeNO system approved for the shorter breath test duration, which the company says helps enable testing in patients who may struggle with longer exhalations, including pediatric and other difficult-to-test populations.

“The US launch of Fenom Flo represents an important expansion of our respiratory diagnostics portfolio,” says Raul Carreras, president of MGC Diagnostics, in a release. “By combining a Food and Drug Administration-approved 6-second breath maneuver with true portability, Fenom Flo supports point-of-care FeNO testing and reflects our commitment to delivering clinically meaningful innovation for real-world care settings.”

Point-of-Care Design for Multiple Settings

Unlike traditional FeNO systems that may require longer breath maneuvers or fixed laboratory setups, Fenom Flo is designed for use at the point of care, including exam rooms and outpatient clinics. The compact design allows clinicians to perform FeNO testing during routine patient visits without specimen collection or preparation.

The device provides non-invasive FeNO measurement to support respiratory assessment using a simple breath maneuver. FeNO testing serves as an adjunct to established clinical assessment across various practice settings.

The system’s portability enables objective measurement of fractional exhaled nitric oxide in more patients and across more care environments, according to the company.

Photo caption: Femon Flo

Photo credit: MGC Diagnostics

Related Reading: